Objective: Endovascular aortic aneurysm repair (EVAR) with a fenestrated device (FEVAR) allows an extension of the proximal sealing zone above the renal arteries to an adequate, healthier segment of the aorta. This feature makes FEVAR an option to treat patients with a diseased aortic neck or type Ia endoleak after EVAR. The aim of this investigation was to present a single-center experience with FEVAR for patients with an abdominal aortic endograft in situ compared with primary FEVAR.
Failure of the proximal seal is among the most important concerns after endovascular aortic aneurysm repair (EVAR). It can result in a secondary type I endoleak and aneurysm progression and rupture. Treatment options depend on the length of the remaining infrarenal aortic neck, the extent of aortic disease, and the degree of graft migration. They include a simple extension of the sealing zone using a cuff device, improvement of graft alignment to the aortic wall using uncovered stents 1 or
EndoAnchors (Aptus Endosystems, Sunnyvale, Calif), 2, 3 implantation of covered parallel grafts, 4 or conversion to open repair. 5 Fenestrated endografts allow for an extension of the proximal sealing zone toward the visceral aortic segment while preserving blood flow to the visceral and renal arteries. Some data have already been published involving the fenestrated Zenith device (Cook Medical Australia, Brisbane, Queensland, Australia) for the treatment of proximal endograft failure. 6, 7 The current investigation was performed to assess our experience with the fenestrated Anaconda endograft (Vascutek/Terumo, Inchinnan, Scotland, United Kingdom) for the salvage of failed previous EVAR compared with primary fenestrated EVAR (FEVAR).
METHODS
This study was approved by the Wilhelminenspital Institutional Review Board, which authorized a waiver of informed consent. The investigation involved the retrospective analysis of a prospectively established clinical database. All patients who underwent treatment with a custom-made Anaconda fenestrated endograft at Wilhelminenspital Department for Vascular and Endovascular Surgery were included. The study period spanned from April 1, 2013, to July 31, 2016.
The American Society of Anesthesiologists (ASA) Physical Status Classification score was assessed preoperatively.
Preoperative and postoperative renal function was monitored by serum creatinine and estimated glomerular filtration rate (eGFR) measurements. Renal insufficiency was defined as an eGFR <60 mL/min/1.73m 2 , and a decrease of the eGFR of >20% at discharge was defined as a significant postoperative deterioration of renal function.
Preoperatively, all patients underwent high-resolution computed tomography angiography imaging (1-mm slice thickness) for case planning. These measurements were used to construct the customized fenestrated endografts.
All procedures were performed in the operating room with the patient under general anesthesia. Initially, a GE C-arm (General Electric Medical Systems, Salt Lake City, Utah) was used; however, most cases were performed under a Ziehm Vision RFD device (Ziehm Imaging GmbH, Nuremberg, Germany).
Antiplatelet therapy and low-molecular-weight heparin were continued perioperatively without administration of a loading dose. Intraoperatively, all patients received unfractionated heparin (5000 IU intravenously). Access was achieved by a bilateral femoral cutdown in all patients, and an additional subclavian access was used in selected patients. The construction of the fenestrated Anaconda graft and the release sequence of this device have been described previously. 8, 9 In contrast to other fenestrated devices currently available, the fenestrated Anaconda graft features a repositioning mechanism that enables the operator to free the proximal sealing rings from the aortic wall as long as the two fixation wires attaching the device to the delivery system have not been pulled. Repositioning can be done around the longitudinal axis as well as upward, and, to a smaller degree, downward. This allows not only for an exact positioning of the graft but also for a minute repositioning that may, however, be impaired as soon as segments of the device distal to the sealing rings make contact with the aortic wall.
The target vessel perfusion rate in relation to the total number of fenestrations was assessed. Technical success was defined according to the recommendations by the Society for Vascular Surgery in 2002, 10 with modifications specific to fenestrated devices, such as the ability to connect all fenestrations to their respective aortic branches and the absence of a type I or type III endoleak, which were assessed by completion angiography and postoperative CT scan (<30 days) or contrast-enhanced ultrasound imaging. Overall functional success, defined as successful exclusion of the aneurysm without type I or type III endoleak or loss of organ function before hospital discharge, was also assessed. The latter might include a failure to connect accessory renal arteries or the celiac trunk in the presence of a stenosis and sufficient collateralization from the superior mesenteric artery, as well as scenarios of secondary technical success through a postoperative intervention to connect a primary unconnected fenestration.
Complications were also classified according to Society for Vascular Surgery recommendations and grouped as deployment-related or systemic and minor (not requiring endovascular or surgical revision, no morbidity upon discharge) or major. 10 Statistics. Variables are presented as mean 6 standard deviation in case of normal distribution and median (range) if data had a skewed distribution. Analyzed outcomes included target vessel perfusion rate, technical success, functional success, 30-day mortality and morbidity, and procedure-related events, including target vessel patency, endoleak, renal function, and reintervention rate at discharge or up to 30 days postoperatively. A c 2 test as well as Fisher and mid-P exact tests were used to compare the categoric outcome of technical success or failure between patients with prior EVAR and those with primary FEVAR. Because of low expected values within the analyses, comparable P values reported are those from the mid-P exact test, as recommended by the software developers. Continuous variables were compared using a t-test or nonparametric equivalent when applicable. A twosided P value of <.05 was considered to indicate statistical significance. Analyses were performed using SPSS 20 software (IBM Inc, Armonk, NY) and OpenEpi 3.01 software (Andrew G. Dean and Kevin M. Sullivan, www.OpenEpi.com).
RESULTS
Patient characteristics. During the study period, 94 individuals were treated with a fenestrated Anaconda device. Average age was 73.0 6 6.0 years, and 76 were men (80.9%). Fifty-nine patients (62.8%) were classified Recommendation: The results suggest low technical success for FEVAR using the Anaconda device for failed EVAR, whereas the rates of aneurysm exclusion, major complications, and late reinterventions were comparable with those observed in patients who underwent primary FEVAR.
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as ASA III and five patients as ASA IV (5.3%). Mean preoperative eGFR was 59.6 6 13.9 mL/min/1.73m 2 .
Treatment indications and characteristics of previous EVAR devices. Treatment indications included primary abdominal aortic aneurysm (AAA) in 54 patients, penetrating aortic ulcer in 8, thoracoabdominal aneurysm in 8, aortoiliac pathology in 11, progressive aortic neck dilatation after open AAA repair in 1, and revision after EVAR in 12. Among the latter patients, 7 were treated for a type Ia endoleak, 2 were treated for stent migration with aneurysm progression but no visible endoleak, and 3 patients were treated for progression of aortic disease at the level of the visceral segment. Devices in situ at the time of FEVAR and previous interventions performed to treat existing endoleaks are listed in Table I . The primary intervention had on average been performed 43 months (range, 2-90 months) previously.
Surgical details. Table II includes patient characteristics, procedural details, deployment-related complications, and success between the two study groups. Grafts were oversized 15% to 25% in respect to the proximal landing zone. There were a mean of 3.0 6 0.9 (range, 1-5) fenestrations. The procedure was technically successful in 79 of 94 patients (84.0%). Eight of the nonsuccessful procedures involved failure to connect a target artery. Of 30 patients with two or fewer fenestrations, none had a primary unconnected fenestration (PUF), and in 64 patients with three or more fenestrations, eight had a PUF (P ¼ .04). Two type III endoleaks were treated with percutaneous transluminal angioplasty during the same hospital stay, and two were initially left untreated. One unconnected left renal artery was connected successfully in the angiography suite #24 hours after surgery. Two patients with unconnected renal arteries lost organ function, and one had to undergo nephrectomy. Three cases of unconnected accessory renal arteries resulted in minor tissue loss with no consecutive renal insufficiency. Two unconnected celiac trunks remained asymptomatic and were left occluded. As a result, functional success was achieved in 94.7%. Besides the two patients with kidney loss, major deployment-related complications included one superior mesenteric artery dissection and one kidney hemorrhage, both eventually fatal. One patient with an infrarenal graft stenosis seen on postoperative CT angiography was successfully treated with graft percutaneous transluminal angioplasty, and one patient with an infrarenal graft occlusion required an axillobifemoral bypass. In addition, access site complications in six patients required revision, one resulting in a major leg amputation. When redo cases and primary FEVARs were compared, primary technical success rates were 58.3% and 87.8% (P ¼ .02) and primary functional success rates were 91.7% and 95.1%, respectively (P ¼ .62).
Perioperative morbidity and mortality. There were no intraoperative deaths and no conversions to open surgery. The 30-day mortality was 5.3%. The difference between mortality rates when redo cases (0% mortality) and patients with primary FEVAR (6.1% mortality) were compared was not statistically significant (P ¼ .5).
Major systemic complications included 3 patients with perioperative stroke (2 ischemic, 1 hemorrhagic), 1 fatal myocardial infarction, and 1 patient with spinal cord ischemia with persistent paraplegia who had also undergone thoracic endovascular aortic repair for a concomitant penetrating aortic ulcer of the proximal descending aorta. One patient underwent acute open cholecystectomy on day 8 after FEVAR, and one patient required a thoracic drainage caused by a central venous catheter-associated pneumothorax.
Overall, no significant increase in creatinine levels was observed from preoperatively to postoperatively (1.1 6 0.3 mg/dL and 1.3 6 0.8 mg/dL, respectively; P ¼ .17). Renal function significantly decreased in 13 patients (13.8%). In summary, the rate of major systemic complications was comparable between redo cases and primary FEVARs (8.3% vs 8.5%, respectively; P ¼ .05). A postoperative CT angiography was performed in 89 patients, and the remaining patients underwent contrast-enhanced ultrasound imaging due to renal insufficiency. There were no early occlusions of connecting stents.
Follow-up data. Six patients died during follow-up, none of aneurysm-related causes. After an average follow-up interval of 10 6 9.5 months (range 0-43 months), no late occlusions of connecting stents were observed. The late reintervention rate was 11.7%, with no statistically significant difference between groups (Table III) . Five patients underwent secondary interventions for eight connecting stents. Six were treated by stent extension and two by percutaneous transluminal angioplasty only. The other cases involved late access vessel complications (n ¼ 2), embolization of type II endoleaks causing sac diameter progression (n ¼ 2), treatment of a persisting type III endoleak (n ¼ 1), and migration of a thoracic tube graft that had been implanted to provide a sufficient proximal sealing zone (n ¼ 1). The rates of late complications and late reinterventions were comparable between groups: 8.3% and 16.7% in redo cases (P ¼ .78) and 12.2% and 11% in primary interventions (P ¼ .57).
DISCUSSION
Salvage of a failed EVAR procedure with a loss of proximal seal can be demanding in patients with a short or no infrarenal neck. Devices that are intended to improve graft alignment to the aortic wall, including the uncovered Palmaz stent (Cordis, Fremont, Calif) 11, 12 or EndoAnchors, 2, 3 showed disappointing midterm results after treatment of secondary type Ia endoleaks. The use of renal or visceral artery stents parallel to the aortic endograft allows an extension of the aortic seal zone into the paravisceral segment, using covered selfexpanding or balloon-expendable stent grafts. 13, 14 Although initial results on the technical feasibility and early results of the chimney technique were very promising, [15] [16] [17] recent reports have been more cautious: 30-day procedure-related major complication rates of 25% to 40% have been published. 18, 19 Limited data exist on the use of the chimney technique for redo cases. Donas et al 20 reported outcomes of 18 interventions for the treatment of proximal seal failure, with a reintervention rate of 22% (n ¼ 4) #17 months. Although the group was relatively small, results underline the challenging nature of this intervention. of patients undergoing redo EVAR with patients undergoing primary fenestrated or branched interventions. Unfortunately, the authors did not differentiate between branched or fenestrated devices; thus, a direct comparison with our data is not possible. For 52 patients undergoing rescue procedures, the technical success rate was 85% and the target vessel perfusion rate was 92%. Although a follow-up interval and target vessel patency were not reported, total reintervention rate was 27%. However, both authors described difficulties with the passage of pretreated iliac arteries and the cannulation of aortic side branches. Iliac artery passage was not an issue in the current series, but the rate of target vessel perfusion was significantly reduced in redo compared with primary cases. According to our own experience, this is caused by the increased friction between the fenestrated graft and the old graft in situ compared with no friction when the fenestrated graft is deployed into a dilated aortic lumen. This interaction also impedes the ability of the Anaconda device to be repositioned. However, the relatively high rate of primary unconnected fenestrations must be interpreted with caution. In most cases, this was not associated with an insufficient treatment of the aneurysm or major complications. Especially in cases of small-caliber renal arteries (<4 mm) or high-grade stenosis of a well-collateralized celiac trunk ostium, not revascularizing that vessel and omitting the respective fenestration from the outset may be a sensible plan.
CONCLUSIONS
Compared with primary FEVAR, redo cases are associated with a higher risk of a failure to connect all fenestrations to their respective target vessels. The identification of this significant effect of history of prior EVAR on primary technical success has obvious implications on preoperative decision making and deserves consideration in the informed consent process. Specifically, a highly stenosed and well-collateralized celiac trunk or smallcaliber accessory renal artery may not warrant inclusion into the graft plan. However, most of the primary unconnected fenestrations remained asymptomatic and did not result in endoleaks. Despite its limitations, FEVAR is a valuable tool for both primary treatment of AAA with an insufficient proximal landing zone as well as for salvage of a failed EVAR or for treating disease progression in the pararenal aorta after endovascular or open therapy for an infrarenal aneurysm.
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